Tim Chiang
Stock Analyst at Capital One
(0.40)
# 3,076
Out of 4,415 analysts
17
Total ratings
31.25%
Success rate
-12.04%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $2.61 | +129.89% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $26.09 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $24.52 | +185.48% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $42.46 | +3.63% | 2 | Jul 29, 2022 | |
| KALA Kala Pharmaceuticals | Maintains: Outperform | $300 → $200 | $7.01 | +2,754.29% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | n/a | $27.21 | - | 2 | May 5, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $3.45 | - | 1 | Oct 28, 2020 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | n/a | $7.26 | - | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical | Upgrades: Neutral | n/a | $13.98 | - | 3 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | n/a | $4.39 | - | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $2.61
Upside: +129.89%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $26.09
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $24.52
Upside: +185.48%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $42.46
Upside: +3.63%
Kala Pharmaceuticals
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $7.01
Upside: +2,754.29%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: n/a
Current: $27.21
Upside: -
Repare Therapeutics
Oct 28, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.45
Upside: -
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $7.26
Upside: -
Teva Pharmaceutical
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $13.98
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: n/a
Current: $4.39
Upside: -